In vitro screens for small molecules that affect intracellular proteins traditionally have relied on binding affinity to select the best candidate compound. However, binding affinity alone does not determine the effects of a small molecule.

With its "molecular braille" approach, Novalon Pharmaceutical Corp. believes it has a tool to screen for small molecules that have specific effects on the function of proteins such as nuclear receptors.